Dr. Vidal received his Ph.D. from Gembloux University (Belgium) with work performed at Northwestern University (USA).  He identified the yeast genes SIN3 and RPD3, and demonstrated that they encode global transcriptional regulators.  RPD3 was later found to encode Histone Deacetylase. During his post-doctoral training at the Massachusetts General Hospital Cancer Center (USA), he developed the reverse two-hybrid system, a method now used by many laboratories to genetically characterize protein-protein interactions. He started his own group in 1997 with the goal of understanding how global and local properties of macromolecular networks relate to biological processes and to human disease. In 2000, he moved his laboratory to the Dana-Farber Cancer Institute (DFCI). He is now Professor of Genetics at Harvard Medical School and Director of the DFCI Center for Cancer Systems Biology (CCSB).